Knowthestock.com
BIIB - Biogen Inc
SNP 500NASDAQ

Sell

Moderate Growth but DecliningStock Price Very High
WeakStrong
WeakStrong

51%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -4.37%
Operating Income Growth is -64.07%
Net Income Growth is -62.74%
Earnings Per Share (EPS) Growth is -62.83%
Net Margin is 12.07%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 2.1
Debt Ratio is 0.43
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.24
Cash Flow is MODERATE
Cash from Operations Growth is -1.95%
Capital Expenditure is High
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Biogen Inc (BIIB) - https://www.biogen.com/
through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
Exchange - NASDAQ
Industry -
Sector -
CEO - Michel Vounatsos
Employees - 13,414
    Close

    Login/Register

    Home


Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2024 and future.